Doctors may soon have a new way to treat high blood pressure, even among people for whom medicines haven’t worked well in the past.
Baxdrostat, an experimental medicine made by AstraZeneca, showed promise in treating people with uncontrolled or resistant high blood pressure in a recent trial. If the medicine gets approved by regulatory authorities, it will be one of the first new approaches to treating high blood pressure in decades, researchers say.
Scientists presented the trial results Saturday at the European Society of Cardiology Congress 2025 in Madrid and simultaneously published them in the New England Journal of Medicine.
For the study, researchers enrolled 800 adults who still had high blood pressure after taking two or more medications for at least four weeks. To qualify for the study, patients’ systolic blood pressure had to be between 140 and 170.
Blood pressure is measured in millimeters of mercury, which is abbreviated as mm Hg. The measurement has an upper number, or systolic reading, and a lower number, a diastolic reading. Systolic pressure measures the force of blood as it pumps out of the heart into the arteries; diastolic is the pressure created as the heart rests between beats.
